News for Zai Lab Limited (ZLAB)

U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Guidewire Software, Inc. GWRE rose sharply during Wednes...

Zai Lab (ZLAB) announced positive Phase 1 data for ZL-1310 at the 2025 ASCO Annual Meeting. The study demonstrated a 67% objective response rate in seco

Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at the 2025 ASCO Annual Meeting, marking the first therapy to show statistically...

The Phase 3 PANOVA-3 trial shows TTFields therapy significantly improves overall survival in pancreatic cancer. TTFields therapy demonstrated a 2-month

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conf

Zai Lab Limited (NASDAQ:ZLAB; HKEX: 9688) will participate in multiple investor conferences in June 2025. The events include the Jefferies Global Health

Zai Lab Limited gains momentum with FDA Fast Track nod and solid earnings, signaling growth potential. Click here to find out why ZLAB stock is a Buy.

Zai Lab's ZL-1310 receives FDA fast-track & orphan drug status for small cell lung cancer. Read more here.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, the Compa

Zai Lab Limited (NASDAQ:ZLAB) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsChristine Chiou - Senior Vice President, Investor...

We recently published a list of 11 Best Breakout Stocks to Buy According to Analysts.

Baron Emerging Markets Fund increased in the first quarter of 2025, outperforming its benchmark, the MSCI EM Index. Read more here.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational onco

Zai Lab Limited (ZLAB) is presenting promising data at the AACR 2025 on two innovative oncology therapies, ZL-6201 and ZL-1222. ZL-6201 is advancing int

Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend su

Zai Lab (ZLAB) is set to present phase 1 trial data for its DLL3-targeted ADC, ZL-1310, at the 2025 ASCO Annual Meeting. The trial focuses on patients w

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial [url="](NCT06179069)[/url] eval

Zai Lab Limited (ZLAB) has received a significant boost as China's National Medical Products Administration has accepted its supplemental new drug application f

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the supplemental New Drug